Fund shareholders of TRAWS PHARMA INC
ISIN US68232V8845 · United States · LEI 549300BRAR7BTG2PIY51
- Fund shareholders
- 7
- Of which ETFs
- 0 7 other funds
- Value held
- 359.6K $
- Share of capital
- 2.5 % of 15.4M shares on Aug 12, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 177,200 | 149.4K $ | 1.15 % | as of Jun 30, 2026 ↗ | |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 152,849 | 128.9K $ | 0.00 % | 0.99 % | as of Jun 30, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 39,339 | 57.4K $ | 0.00 % | 0.26 % | as of May 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 8,098 | 11.8K $ | 0.05 % | as of May 31, 2026 ↗ | |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 7,466 | 10.9K $ | 0.05 % | as of May 31, 2026 ↗ | |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 743 | 1.1K $ | 0.00 % | as of May 31, 2026 ↗ | |
| Blackstone Alternative Multi-Strategy Fund Blackstone Alternative Investment Funds | 11 | 9.3 $ | 0.00 % | as of Jun 30, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of May 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Jun 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q3 | 7 | +2 | 385,706 | +242.7 % |
| 2026Q2 | 5 | 0 | 112,552 | +22.6 % |
| 2026Q1 | 5 | 0 | 91,787 | -0.2 % |
| 2025Q4 | 5 | 0 | 92,015 | +109.9 % |
| 2025Q3 | 5 | 0 | 43,829 | +13.9 % |
| 2025Q2 | 5 | 0 | 38,491 | +82.0 % |
| 2025Q1 | 5 | +2 | 21,144 | -21.8 % |
| 2024Q4 | 3 | 27,023 |
Institutional managers
23 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 730,000 | 1.3M $ | as of Mar 31, 2026 |
| Ikarian Capital, LLC | 678,142 | 1.2M $ | as of Mar 31, 2026 |
| ORBIMED ADVISORS LLC | 605,531 | 1.1M $ | as of Mar 31, 2026 |
| Squadron Capital Management LLC | 511,714 | 936.4K $ | as of Mar 31, 2026 |
| Dauntless Investment Group, LLC | 416,998 | 763.1K $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 194,536 | 356K $ | as of Mar 31, 2026 |
| ADAR1 Capital Management, LLC | 154,098 | 282K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 77,103 | 141.1K $ | as of Mar 31, 2026 |
| Palumbo Wealth Management LLC | 61,175 | 112K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 25,802 | 47.2K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 21,241 | 38.9K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 19,244 | 35.2K $ | as of Mar 31, 2026 |
| Lynx1 Capital Management LP | 15,078 | 27.6K $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 9,956 | 18.2K $ | as of Mar 31, 2026 |
| UBS Group AG | 4,053 | 7.4K $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 3,964 | 7.3K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 3,729 | 6.8K $ | as of Mar 31, 2026 |
| SBI Securities Co., Ltd. | 128 | 234 $ | as of Mar 31, 2026 |
| FMR LLC | 23 | 42 $ | as of Mar 31, 2026 |
| Cassaday & Co Wealth Management LLC | 11 | 21 $ | as of Mar 31, 2026 |
| JONES FINANCIAL COMPANIES LLLP | 2 | 4 $ | as of Mar 31, 2026 |
| Caitong International Asset Management Co., Ltd | 2 | 4 $ | as of Mar 31, 2026 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2 | 4 $ | as of Mar 31, 2026 |
Declared shareholders of TRAWS PHARMA INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| Sirenia Capital Management LP and 1 other | 9.90 % | 6,565,474 | as of Jun 30, 2026 · SCHEDULE 13G |
| Ikarian Capital, LLC and 1 other | 9.50 % | 1,555,423 | as of Jun 30, 2026 · SCHEDULE 13G |
| Adage Capital Management, L.P. and 2 others | 4.79 % | 730,000 | as of Jun 30, 2026 · SCHEDULE 13G |
| Squadron Master Fund LP and 3 others | 0.00 % | 0 | as of Jun 30, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Fund shareholders of TRAWS PHARMA INC". https://titelia.com/en/stocks/traws-pharma-inc-US68232V8845